RxDoctor Payments DataLook up a doctor →

Mahmoud Mustafa, MD

Internal Medicine · Washington, DCNPI 1437118197

Payments from drug & device makers

$36,935in general payments, 2019–2025

Across 900 payments — averaging $41.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$19K
  • Viiv Healthcare Company$5K
  • Theratechnologies Inc.$3K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Pfizer$1K
  • plus $7K from 46 others

What the payments were for

  • Consulting fees$1,2003%
  • Speaking & faculty fees$13,91938%
  • Travel & lodging$2,3296%
  • Food & beverage$19,19052%
  • Education$2971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,935 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$48,037
Medicare patients
123
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin14$279,355
BiktarvyBictegrav/Emtricit/Tenofov Ala34$180,821
JulucaDolutegravir/Rilpivirine26$105,221
DovatoDolutegravir Sodium/Lamivudine23$102,682
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$69,585
TivicayDolutegravir Sodium25$55,525
PrezcobixDarunavir/Cobicistat14$52,055
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$50,921
Darunavir28$39,432
OzempicSemaglutide26$34,374
PifeltroDoravirine17$29,366
Etravirine20$25,945
XareltoRivaroxaban23$21,691
JardianceEmpagliflozin24$16,728
EliquisApixaban12$15,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$4,828$263,42874 claims
GileadBiktarvy, Genvoya$18,555$250,40648 claims
Johnson & JohnsonPrezcobix, Xarelto$899$73,74637 claims
Novo NordiskOzempic$323$34,37426 claims
MerckPifeltro$756$29,36617 claims
Boehringer IngelheimJardiance$23$16,72824 claims
PfizerEliquis$1,114$15,70712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →